advanced search

EXPERT VIEW

SHEAR RELIEF: MINIMISING SHEAR STRESS IN CGT PRODUCTION
EXPERT VIEW
Dr Ethan Miller
SHEAR RELIEF: MINIMISING SHEAR STRESS IN CGT PRODUCTION
Dr Ethan Miller examines the manufacturing of cell and gene therapies where shear stress can impact cells and explores strategies to mitigate such damage, helping to ensure that therapies retain their viability, functionality and therapeutic potency from production through to administration.
PRECISION DELIVERY: THE MISSING LINK IN CELL & GENE THERAPY
EXPERT VIEW
Jessica Alzamora
PRECISION DELIVERY: THE MISSING LINK IN CELL & GENE THERAPY
Jessica Alzamora, Dr Karla Sanchez and Emily Chang discuss the necessity for precision when delivering cell and gene therapies, explore how this precision can be designed and demonstrated, then go on to describe how a minimum viable product approach to device development can act as a strong predictor of a successful delivery device.
DRUG DELIVERY DEVICE INNOVATION IN CELL AND GENE THERAPIES
EXPERT VIEW
Alejandra Sanchez
DRUG DELIVERY DEVICE INNOVATION IN CELL AND GENE THERAPIES
Dr Alejandra Sanchez and Charlie Dean consider the evolution of drug delivery technologies and how cell and gene therapies are showing promise as a new class of medicine to correct disease at its source.
RESPIRATORY MUCOSAL VACCINATION: HOW COULD WE DELIVER ANOTHER GLOBAL VACCINATION RESPONSE WITH CURRENT DEVICE TECHNOLOGIES?
EXPERT VIEW
Mark Parry
RESPIRATORY MUCOSAL VACCINATION: HOW COULD WE DELIVER ANOTHER GLOBAL VACCINATION RESPONSE WITH CURRENT DEVICE TECHNOLOGIES?
Mark Parry discusses the potential needs and opportunities for respiratory drug delivery devices in the context of a hypothetical global vaccination strategy, considering a variety of factors and how different respiratory device approaches could perform.
STRESS-TESTING INHALED MEDICINE SO PATIENTS CAN BREATHE EASIER
EXPERT VIEW
Dr Yannick Baschung
STRESS-TESTING INHALED MEDICINE SO PATIENTS CAN BREATHE EASIER
Dr Yannick Baschung discusses the benefits and challenges of orally inhaled and nasal drug products and examines how drug developers can stress test their products to improve regulatory success and patient safety, as well as how partnering with an expert CRO can provide an efficient way of performing critical characterisation testing.
DISSOLUTION TESTING FOR ORALLY INHALED PRODUCTS: CONFRONTING THE CHALLENGES, REALISING THE POTENTIAL
EXPERT VIEW
Jamie Clayton
DISSOLUTION TESTING FOR ORALLY INHALED PRODUCTS: CONFRONTING THE CHALLENGES, REALISING THE POTENTIAL
As dissolution testing rises up the agenda for orally inhaled product developers, Jamie Clayton explores drivers behind its adoption and key considerations for developing a robust and relevant method.
HOW CUTTING EDGE IN SILICO APPROACHES CAN REDUCE TIME AND RISK IN DEVELOPMENT OF INHALATION DEVICES
EXPERT VIEW
Dr Peter Harley
HOW CUTTING EDGE IN SILICO APPROACHES CAN REDUCE TIME AND RISK IN DEVELOPMENT OF INHALATION DEVICES
Dr Peter Harley, Mariam Al-Amari and Matt Jones explore how in silico approaches can transform pulmonary and nasal drug delivery device development, illustrating through case studies – spanning low-global-warming potential propellants, assembly robustness, device-user interaction, variability and capsule piercing dynamics – how simulation-led in silico approaches can improve understanding of device performance and identify risks early, reducing development costs and accelerating the path to more reliable, innovative and patient-friendly drug-device systems.
DELIVERING AND MAINTAINING OPTIMAL DPI PERFORMANCE
EXPERT VIEW
Chris Gilmor
DELIVERING AND MAINTAINING OPTIMAL DPI PERFORMANCE
Chris Gilmor considers the issues affecting dry powder inhalers and explains how formulators use a range of techniques to ensure dose dispersion and API detachment. He goes on to explain the importance of controlling the moisture level in these devices and how it can affect the drug delivery performance of the formulation.
SUSTAINABLE DRUG DELIVERY SYSTEMS: COLLABORATIVE INNOVATION TO SHRINK PHARMA’S PACKAGING FOOTPRINT
EXPERT VIEW
Maria Riccius
SUSTAINABLE DRUG DELIVERY SYSTEMS: COLLABORATIVE INNOVATION TO SHRINK PHARMA’S PACKAGING FOOTPRINT
Maria Riccius and Dr Uwe Hanenberg explore how CDMOs are playing a pivotal role in driving drug delivery’s transformation towards sustainability, examining the most promising advances and highlighting why collaborative innovation is essential to achieving measurable environmental gains, both within organisations and across the pharmaceutical value chain.
SUSTAINABILITY AS STRATEGY: HOW PHARMA IS DRIVING CLIMATE INNOVATION
EXPERT VIEW
Dr Sofia Sotiropoulou
SUSTAINABILITY AS STRATEGY: HOW PHARMA IS DRIVING CLIMATE INNOVATION
Dr Sofia Sotiropoulou discusses the increasing emphasis that pharma companies are putting on sustainability metrics, and how they are extending this emphasis to their entire supply chains, placing expectations on design and manufacturing partners to participate in meeting sustainability targets.
AUTOINJECTORS VERSUS ON-BODY SYSTEMS: THE FUTURE OF LARGE-VOLUME DELIVERY
EXPERT VIEW
Dr Alex Vasiev
AUTOINJECTORS VERSUS ON-BODY SYSTEMS: THE FUTURE OF LARGE-VOLUME DELIVERY
Dr Alex Vasiev and Dr Ethan Miller weigh up the benefits and costs of using on-body injectors versus autoinjectors, discussing delivery, design and patient population variability alongside recent advances in on-body injector development.
FROM HOSPITAL TO HOME HEALTHCARE: ADVANCES IN LYOPHILISED PRODUCT DELIVERY
EXPERT VIEW
Edward Trappler
FROM HOSPITAL TO HOME HEALTHCARE: ADVANCES IN LYOPHILISED PRODUCT DELIVERY
Edward Trappler, Denise Miller and Michael Thomas discuss the challenges for lyophilised products and consider the role of dual-chamber devices in simplifying reconstitution, particularly for at-home healthcare products, and go on to look at how future advances in delivery devices are providing safe solutions for self-administration while improving patient adherence.
POWDER TO THE PEOPLE: ACCELERATING ACCESS TO LYOPHILISED THERAPIES
EXPERT VIEW
Kristien De Clercq
POWDER TO THE PEOPLE: ACCELERATING ACCESS TO LYOPHILISED THERAPIES
Kristien De Clercq and Dr Alex Vasiev discuss the challenges and recent advances in drying and reconstitution technologies, as well as how, while dual-chamber primary packaging offers a potential solution for simplifying reconstitution, it remains underused due to usability concerns and a prevailing industry preference for vial-based lyophilisation over alternative drying methods such as spray drying and powder filling.
DELIVERING COMPLEXITY: DEVICE CONSIDERATIONS FOR TWO-COMPONENT INJECTABLE FORMULATIONS
EXPERT VIEW
María FM Balson
DELIVERING COMPLEXITY: DEVICE CONSIDERATIONS FOR TWO-COMPONENT INJECTABLE FORMULATIONS
María FM Balson weighs up strengths and limitations when developing devices for lyophilised injectables, exploring their growing demand and the impacts of formulation, device type and design on the feasibility for bringing a device to market to deliver these essential therapies.
ADVANCING CANCER CARE THROUGH ON-BODY SUBCUTANEOUS INJECTIONS: THE ONCOLOGY COMMUNITY’S PERSPECTIVE
EXPERT VIEW
Dr Greg Moakes
ADVANCING CANCER CARE THROUGH ON-BODY SUBCUTANEOUS INJECTIONS: THE ONCOLOGY COMMUNITY’S PERSPECTIVE
Dr Greg Moakes discusses the role that on-body delivery systems have to play in modernising the delivery of oncology drugs, digging into the survey results of over 200 attendees of the American Society of Clinical Oncology 2025 Global Meeting as to their opinions on the place of this pivotal technology in oncological practice.
SAFE AND SKIN-FRIENDLY MANUFACTURING OF MEDICAL WEARABLES WITH ULTRASONIC WELDING
EXPERT VIEW
Michael Boerner
SAFE AND SKIN-FRIENDLY MANUFACTURING OF MEDICAL WEARABLES WITH ULTRASONIC WELDING
Michael Boerner looks at the key factors for designing skin-friendly medical wearables and how to manufacture them safely, automatically and sustainably.
MASTERING COMMERCIAL MANUFACTURING FOR STERILE INJECTABLES
EXPERT VIEW
Jennifer Gattari
MASTERING COMMERCIAL MANUFACTURING FOR STERILE INJECTABLES
Jennifer Gattari delves into what is required to succeed at the commercial phase of sterile injectable manufacturing, going on to explore the challenges that companies can expect and the critical strategies that can help ensure a smooth and scalable journey to market.
PRESSURE ON THE SUPPLY CHAIN: TARIFFS, REGULATIONS AND TRANSPARENCY
EXPERT VIEW
Jacob Tyson
PRESSURE ON THE SUPPLY CHAIN: TARIFFS, REGULATIONS AND TRANSPARENCY
Jacob Tyson and Jon Lawrence consider the changes in the regulatory landscape for medical device manufacturers; the critical role that suppliers, distributors and importers play in ensuring effective post-market surveillance; and the technologies that companies are adopting to support traceability solutions.
HARNESSING X-RAY AND AI FOR A NEW ERA OF QUALITY CONTROL
EXPERT VIEW
Dr Richard Parmee
HARNESSING X-RAY AND AI FOR A NEW ERA OF QUALITY CONTROL
Dr Richard Parmee discusses the multitudinous applications of X-ray inspection technology for high-speed pharmaceutical production lines, covering the value of introducing artificial intelligence and machine learning techniques to enhance detection and improve safety.
NAVIGATING SEMICONDUCTOR LIFECYCLE CHALLENGES IN MEDTECH: A STRATEGIC SHIFT TOWARDS ASICs
EXPERT VIEW
Andy Kelly
NAVIGATING SEMICONDUCTOR LIFECYCLE CHALLENGES IN MEDTECH: A STRATEGIC SHIFT TOWARDS ASICs
Andy Kelly considers the evolution of semiconductor technology and the impact of the release of new and upgraded components. This article discusses how strategic decisions during the early stages of product design can determine the future viability of a medical device and considers the cost savings offered by application-specific integrated circuits through a reduction in the number of components required.
CONNECTED BUT PROTECTED – SECURELY CONNECTING DRUG DELIVERY DEVICES
EXPERT VIEW
Dr Joachim Wilke
CONNECTED BUT PROTECTED – SECURELY CONNECTING DRUG DELIVERY DEVICES
Dr Joachim Wilke discusses wireless connectivity in novel drug delivery devices, highlighting the possibilities for improved patient outcomes and care, the associated security risks, as well as examining the wide range of cyber security solutions and standards to mitigate these issues.
SMART ENOUGH: DESIGNING DRUG DELIVERY DEVICES THAT PUT PATIENTS FIRST
EXPERT VIEW
Andy Pidgeon
SMART ENOUGH: DESIGNING DRUG DELIVERY DEVICES THAT PUT PATIENTS FIRST
Andy Pidgeon  challenges the assumption that more advanced technology is always better, re-examining the design approach to connected autoinjectors from the patient perspective and highlighting the value of simplicity and usability – digging into the idea that, by investigating the real-world needs of patients, drug delivery device designers can ensure that their devices are serving those needs, rather than creating unnecessary new challenges for users.
A STICKY ISSUE: TRANSFORMING OILY PLANT EXTRACTS INTO SOLID ORAL DOSAGE FORMS
EXPERT VIEW
Dr Maj-Britt Cepok
A STICKY ISSUE: TRANSFORMING OILY PLANT EXTRACTS INTO SOLID ORAL DOSAGE FORMS
Dr Maj-Britt Cepok discusses the increasing prevalence of plant extracts in the oral solid dosage market, considering how the common physical properties of these ingredients can both provide benefits and pose a challenge to formulators looking to capitalise on this rapidly growing market segment.
RETHINKING GLP-1 DELIVERY DEVICES: DESIGNING FOR USERS BEYOND DIABETES
EXPERT VIEW
Dan Lock
RETHINKING GLP-1 DELIVERY DEVICES: DESIGNING FOR USERS BEYOND DIABETES
Dan Lock explores how the experiences and motivations of individuals using glucagon-like peptide 1 drugs for weight loss may differ from those managing diabetes or heart disease.
Top